Nasdaq

Disc Medicine Highlights Positive Clinical Data for Bitopertin, DISC-0974, and DISC-3405 at EHA 2025; Management to Host Corporate Update Call

Disc Medicine announces positive updates on bitopertin, DISC-0974, and DISC-3405, with plans for upcoming clinical trials and data presentations. Disc Medicine, Inc. recently provided positive updates ...
Nasdaq

Disc Medicine, Inc. to Present Key Data from Hematology Portfolio at EHA 2025 Congress

Disc Medicine, Inc. announced it will present data from its hematology portfolio at the European Hematology Association (EHA) 2025 Congress in Milan from June 12-15, 2025. The presentations will ...
The Manila Times

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO ...

Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor ...
Seeking Alpha

Disc Medicine: RALLY-MF Data Validates Pipeline Optionality

Disc Medicine is well-capitalized, with over $800M in cash, ensuring operational runway through 2029 regardless of bitopertin's launch success. Bitopertin’s NDA is submitted, aiming for accelerated ...